09/06/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
09/06/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
05/10/2018 “BioChaperone® technology enables the development of pramlintide-prandial insulin combinations” (Poster 811), presented by Dr. Remi Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
26/06/2018 BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
25/06/2018 BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
Rejoignez notre liste de diffusion. S'abonner